万维提示：
1、投稿方式：在线投稿。
2、期刊网址：https://www.springer.com/journal/10120
3、投稿网址：https://www.editorialmanager.com/gcan
4、官网邮箱：相关咨询邮箱如下。
5、期刊刊期：双月刊，逢单月出版。
2021年5月25日星期二
相关咨询邮箱【官网信息】
Contact the journal
Submission-related enquiries
Queries about submission issues, peer review process, or the status of your manuscript should be sent to Jayaraman Seetharaman (Jayaraman.Seetharaman@springernature.com).
Publication-related enquiries
Queries about accepted manuscripts in production or post-publication corrections should be sent to Saravanan Babu (Saravanan.Babu@springer.com).
Other editorial enquiries
Any other queries about the journal or presubmission enquiries should be sent to Yoko Arai (yoko.arai@springer.com).
投稿须知【官网信息】
Submission guidelines
Instructions for Authors
Scope
Gastric Cancer, a joint official journal of the international Gastric Cancer Association and the Japanese Gastric Cancer Association, publishes significant studies related to stomach neoplasms. Original articles (up to 4000 words, excluding references, with no more than seven figures/tables in total), Case reports (up to 1500, excluding references, with no more than seven figures/tables in total), Short communications (up to 1500 words, excluding references, with no more than four figures/tables in total), and Technical notes (up to 1500 words, excluding references, with no more than seven figures/tables in total) will be peer-reviewed for publication on the understanding that the study has not been submitted simultaneously to or accepted by another journal. The criteria for acceptance are originality and high scientific quality. Review articles (up to 5000 words, excluding references, with no more than seven figures/tables in total) are in principle solicited by the Editor, but unsolicited manuscripts will also be considered. With regard to the submission of meta-analysis studies, the journal’s editorial board will only consider studies that analyze individual patients’ data from randomized clinical trials. In principle, the journal will not accept studies on meta-analyses based on tabulated data. Letters to the Editor (up to 500 words, excluding references, with no figure/table) commenting on articles published in the journal or expressing views on topics of gastric cancer are welcomed. Meeting reports, at the request of the Editor, will include summaries of symposia or consensus achieved in the congresses of related associations.
Clinical Trial Registration
Any clinical trial for which patient enrollment began on or after January 1, 2014 must be registered. Authors have 6 months from the first patient enrollment to register the trial, but Gastric Cancer recommends registration prior to enrollment. This registration policy applies to prospective, randomized, controlled trials only.
Gastric Cancer follows the International Committee of Medical Journal Editors (ICMJE), which uses the World Health Organization's definition of a clinical trial. The ICMJE defines a clinical trial as "Any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.' Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration."
The ICMJE lists the following registries as fully compliant:
Australian New Zealand Clinical Trials Registry
ClinicalTrials.gov
ISRCTN Register
UMIN Clinical Trials Registry
Netherlands Trial Register
Brazilian Clinical Trials Registry (ReBec)
Chinese Clinical Trial Registry (ChiCTR)
Clinical Research Information Service (CRiS), Republic of Korea
Clinical Trials Registry - India (CTRI)
Cuban Public Registry of Clinical Trials(RPCEC)
EU Clinical Trials Register (EU-CTR)
German Clinical Trials Register (DRKS)
Iranian Registry of Clinical Trials (IRCT)
Japan Primary Registries Network (JPRN)
Thai Clinical Trials Registry (TCTR)
Pan African Clinical Trial Registry (PACTR)
Sri Lanka Clinical Trials Registry (SLCTR)
Upon submission, authors must provide the registration identification number and the URL for the trial's registry.
Authors can post their results in clinical trial registries as part of these requirements without it being considered previously published or overlapping publication.
Authors also must agree to submit the original protocol upon request from the editorial committee.
Ethical Standards
Gastric Cancer has adopted the Uniform Requirements for Manuscripts (URM) established by the International Committee of Medical Journal Editors (http://www.icmje.org/). The editors reserve the right to reject manuscripts that do not comply with the below-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the below-mentioned requirements.
Human rights statement and informed consent:
For studies involving human subjects, the following statement should be included before the References section:
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.
If doubts arise as to whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.
Identifying information of patients or human subjects – including their names, initials, addresses, admission dates, hospital numbers, or any other data that could be used to identify them – should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or their parent guardian) gives written informed consent to publish. If any identifying information about patients is included in the article, the following sentence should also be included:
Additional informed consent was obtained from all patients for which identifying information is included in this article.
For retrospective studies, the authors are not expected to have consent to participate, however, ethics approval is required. If the manuscript includes any potentially identifiable patient images or data, the authors also need to obtain informed consent.
Animal studies:
For studies with animals, include the following sentence before the References section:
All institutional and national guidelines for the care and use of laboratory animals were followed.
For articles that do not contain studies with human or animal subjects performed by any of the authors, while it is not absolutely necessary, we recommend to include the following sentence, just to make sure that readers are aware that there are no ethical issues with human or animal subjects:
This article does not contain any studies with human or animal subjects performed by any of the authors.
Disclosure of potential conflicts of interest
Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of a real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. Examples of potential conflicts of interests that are directly or indirectly related to the research may include but are not limited to the following:
Research grants from funding agencies (please give the research funder and the grant number)
Honoraria for speaking at symposia
Financial support for attending symposia
Financial support for educational programs
Employment or consultation
Support from a project sponsor
Position on advisory board or board of directors or other type of management relationships
Multiple affiliations
Financial relationships, for example equity ownership or investment interest
Intellectual property rights (e.g. patents, copyrights and royalties from such rights)
Holdings of spouse and/or children that may have financial interest in the work
In addition, interests that go beyond financial interests and compensation (non-financial interests) that may be important to readers should be disclosed. These may include but are not limited to personal relationships or competing interests directly or indirectly tied to this research, or professional interests or personal beliefs that may influence your research.
The corresponding author collects the conflict of interest disclosure forms from all authors. In author collaborations where formal agreements for representation allow it, it is sufficient for the corresponding author to sign the disclosure form on behalf of all authors. The “ICMJE Uniform Disclosure Form for Potential Conflicts of Interest” available at http://www.icmje.org/downloads/coi_disclosure.pdf should be used.
The corresponding author will include a summary statement in the text of the manuscript in a separate section before the reference list, that reflects what is recorded in the potential conflict of interest disclosure form(s).
See below examples of disclosures:
Funding: This study was funded by X (grant number X).
Conflict of Interest: Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.
If no conflict exists, the authors should state:
Conflict of Interest: The authors declare that they have no conflict of interest.
ICMJE Uniform Disclosure Form for Potential Conflicts of Interest
Manuscript submission via Editorial Manager
Authors should submit their manuscripts to Gastric Cancer online. Please log in directly at: https://www.editorialmanager.com/gcan and upload your manuscript following the instructions given on the screen. Please use the Help option to see the most recently updated system requirements.
https://www.editorialmanager.com/gcan
Preparation of manuscript
Manuscript format and style should be in accordance with the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” (http://www.icmje.org). Type the manuscript double-space throughout with margins of at least 25mm. Number pages consecutively, beginning with the title page.
Title page:
The title page should include 1) the type of article (e.g., original article, case report, etc.); 2) the title of the article; 3) the names of the authors; 4) the name(s) of the department(s) and institution(s) to which the work should be attributed; 5) the name and address of the author responsible for correspondence on the manuscript, with their phone and fax numbers and e-mail address (The corresponding author should be the one who assumes primary responsibility for communications with the journal as stated in the ICMJE Recommendations. Regarding the authorship, Gastric Cancer also does not permit multiple last authors.); 6) a short running head of no more than 40 characters (including spaces); and 7) the word count for the article (please note the word limit for each type of article).
Abstract, mini-abstract, and key words:
The second page should carry an abstract of no more than 250 words. In addition, a miniabstract summarizing the significant conclusion of the study within 30 words should be submitted to appear in the table of contents. The abstracts of Original articles should be structured into four paragraphs: Background, Methods, Results, and Conclusions. Authors should provide three to five key words using terms from the medical subject headings (MeSH) list of Index Medicus.
References:
References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in text, tables, and legends by Arabic numerals in square brackets on the line, e.g., Ames et al. [1] reported...
Restrict citations, as far as possible, to papers written in English or with an English abstract. Use the style of the examples below, which are based on the formats used by the U.S. National Library of Medicine (NLM) in Index Medicus (http://www.nlm.nih.gov). List the first six authors followed by et al. The references must be verified by the authors against the original documents.
1. Journal article
Jacobson MA, Zegans M, Pavan PR, O’Donnell JJ, Sattler F, Rao N, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997;349:1443–5.
2. Journal article by DOI
Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009. doi: 10.1016/S0140-6736(09)60879-5.
3. Book chapter
Lefor AT, Flowers JL, Bailey RW. Laparoscopy in gastrointestinal malignancies. In: Wanebo HJ, editor. Surgery for gastrointestinal cancer: a multidisciplinary approach. 2nd ed. Philadelphia: Lippincott-Raven Publisher; 1997. pp. 145–59.
Tables:
Type each table with double spacing on a separate page. Number tables consecutively in the order of their first citation in the text and supply a brief title for each. Give each column a short or abbreviated heading. Place explanatory matter in footnotes, not in the heading. Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body. Explain in footnotes all nonstandard abbreviations that are used in each table. Identify statistical measures of variations, such as standard deviation and standard error of the mean.
Figures:
All figures should be cited in the text and numbered consecutively throughout. Letters, numbers, and symbols should be clear and even throughout and of sufficient size that when reduced for publication each item will still be legible. Figure parts should be identified by lowercase roman letters (a, b, etc.). If illustrations are supplied with uppercase labeling, lowercase letters will still be used in the figure legends and citations. Color figures will always be published in color. For more information about preparing illustrations, please refer to the artwork guidelines available at the end of this document.
Legends for figures:
Type legends for figures using double spacing, starting on a separate page, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend.
Units of measurement:
Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter) or their decimal multiples. All hematologic and clinical chemistry measurements should be reported using the metric system of the International System of Units (SI).
Abbreviations and symbols:
Use only standard abbreviations. Avoid abbreviations in the title and abstract. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement.
Case report
Gastric Cancer publishes case reports with new findings. The following will be considered for publication. (A) Cases that have an important clinical impact: 1) Remarkable effects of a new therapy for gastric cancer; 2) Previously unreported adverse events in treatments for gastric cancer; 3) Novel suggestions or pitfalls in diagnosing gastric cancer; (B) Cases that may provide significant clues to the etiology or natural history of gastric cancer:
1) Combinations of gastric cancer and other diseases in which molecular biological findings provide new etiological information; 2) Previously unreported subtypes, syndromes, or familial accumulations of gastric cancer; 3) Untreated disappearance or long-term stable conditions of gastric cancer, including proof; 4) Previously unreported metastatic or progressive patterns of gastric cancer.
Reports of the following cases will not be accepted for publication. 1) Coincidental combination of gastric cancer and other diseases with no new etiological information;
……
更多详情：
https://www.springer.com/journal/10120/submission-guidelines
